Mu Opioid Receptor Antibody
(Synonyms: MOR1, OPRM1, Mu-type opioid receptor, M-OR-1, MOR-1, Mu opiate receptor, Mu opioid receptor, MOP, hMOP)Mu Opioid Receptor Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Mu Opioid Receptor.
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, IHC-P, ICC/IF
-
Reactivity :
Human, Mouse, Rat
-
Formulation:
Supplied in PBS (pH 7.4), containing 30% glycerol, and 0.01% sodium azide.
-
Conjugation:
Non-conjugated
Applications
| Application |
WB
WB: Western Blot
|
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
|---|---|---|---|
| Dilution Ratio | 1:1000-2000 | 1:100-200 | 1:50-200 |
Product Details
Mu Opioid Receptor Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Mu Opioid Receptor.
-
Host Rabbit
-
Clonality Polyclonal
-
Species ReactivityHuman, Mouse, Rat
-
Observed Molecular WeightObserved band size: 45; 90 kDaNote: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 44 kDa
Synthetic peptide corresponding to the C-term region of human Mu Opioid Receptor.
Endogenous
affinity purified.
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS (pH 7.4), containing 30% glycerol, and 0.01% sodium azide.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
Mu Opioid Receptor is a Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Also activated by enkephalin peptides, such as Met-enkephalin or Met-enkephalin-Arg-Phe, with higher affinity for Met-enkephalin-Arg-Phe (By similarity). Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G protein complex and subsequent exchange of GDP for GTP in the G protein alpha subunit leading to dissociation of the G protein complex with the free GTP-bound G protein alpha and the G protein beta-gamma dimer activating downstream cellular effectors. The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extent to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15. They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B (By similarity). Also couples to adenylate cyclase stimulatory G alpha proteins (By similarity). The selective temporal coupling to G proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4 (By similarity). Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization (By similarity). Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G protein thus terminating signal transduction (By similarity). The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins (By similarity). The activation of the ERK pathway occurs either in a G protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation (By similarity). Acts as a class A G protein-coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling (By similarity). Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G protein coupling (By similarity). Endogenous ligands induce rapid desensitization, endocytosis and recycling (By similarity). Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties (By similarity)[1][2][3][4][5][6][7][8][9].
-
Subcellular Localization
Cell membrane; Cell projection, axon; Perikaryon; Cell projection, dendrite; Endosome
-
Expression
Tissue_Specificity: Expressed in brain. Isoform 16 and isoform 17 are detected in brain. -
Isoforms & Post-Translational Modification
Mu Opioid Receptor has 18 isoforms, P35372-1: amino acid length is 400, molecular weight is 44779 Da (predicted); P35372-2: amino acid length is 392, molecular weight is 43957 Da (predicted); P35372-3: amino acid length is 446, molecular weight is 49520 Da (predicted); P35372-4: amino acid length is 403, molecular weight is 44928 Da (predicted); P35372-5: amino acid length is 418, molecular weight is 47032 Da (predicted); P35372-6: amino acid length is 402, molecular weight is 45096 Da (predicted); P35372-7: amino acid length is 406, molecular weight is 45544 Da (predicted); P35372-8: amino acid length is 397, molecular weight is 44743 Da (predicted); P35372-9: amino acid length is 420, molecular weight is 47070 Da (predicted); P35372-10: amino acid length is 493, molecular weight is 55045 Da (predicted); P35372-11: amino acid length is 389, molecular weight is 43588 Da (predicted); P35372-12: amino acid length is 300, molecular weight is 34393 Da (predicted); P35372-13: amino acid length is 319, molecular weight is 36516 Da (predicted); P35372-14: amino acid length is 314, molecular weight is 36240 Da (predicted); P35372-15: amino acid length is 292, molecular weight is 33570 Da (predicted); P35372-16: amino acid length is 128, molecular weight is 13544 Da (predicted); P35372-17: amino acid length is 101, molecular weight is 10451 Da (predicted); P35372-18: amino acid length is 186, molecular weight is 20188 Da (predicted).
Phosphorylated. Differentially phosphorylated in basal and agonist-induced conditions. Agonist-mediated phosphorylation modulates receptor internalization. Phosphorylated by GRK2 in a agonist-dependent manner. Phosphorylation at Tyr-168 requires receptor activation, is dependent on non-receptor protein tyrosine kinase Src and results in a decrease in agonist efficacy by reducing G protein coupling efficiency. Phosphorylated on tyrosine residues; the phosphorylation is involved in agonist-induced G protein-independent receptor down-regulation. -
Subunit
Forms homooligomers and heterooligomers with other GPCRs, such as OPRD1, OPRK1, OPRL1, NPFFR2, ADRA2A, SSTR2, CNR1 and CCR5 (probably in dimeric forms).
-
SwissProt ID
-
Synonyms
MOR1, OPRM1, Mu-type opioid receptor, M-OR-1, MOR-1, Mu opiate receptor, Mu opioid receptor, MOP, hMOP
Documentation
References
[1]. Zhang P, et al. Mutation of human mu opioid receptor extracellular "disulfide cysteine" residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane. Brain Res Mol Brain Res. 1999 Oct 1;72(2):195-204. [Content Brief]
[2]. Pan YX, et al. Identification and characterization of two new human mu opioid receptor splice variants, hMOR-1O and hMOR-1X. Biochem Biophys Res Commun. 2003 Feb 21;301(4):1057-61. [Content Brief]
[3]. Mestek A, et al. The human mu opioid receptor: modulation of functional desensitization by calcium/calmodulin-dependent protein kinase and protein kinase C. J Neurosci. 1995 Mar;15(3 Pt 2):2396-406. [Content Brief]
[4]. Wang JB, et al. Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett. 1994 Jan 31;338(2):217-22. [Content Brief]
[5]. Bare LA, et al. Expression of two variants of the human mu opioid receptor mRNA in SK-N-SH cells and human brain. FEBS Lett. 1994 Nov 7;354(2):213-6. [Content Brief]
[6]. Bond C, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9608-13. [Content Brief]
[7]. Law PY, et al. Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol. 2000;40:389-430. [Content Brief]
[8]. Lopez A, et al. Membrane functional organisation and dynamic of mu-opioid receptors. Cell Mol Life Sci. 2009 Jul;66(13):2093-108. [Content Brief]
[9]. Massotte D, et al. Agonists activate Gi1 alpha or Gi2 alpha fused to the human mu opioid receptor differently. J Neurochem. 2002 Jun;81(6):1372-82. [Content Brief]